Key result
Late gadolinium enhancement was present in 10.4% of cancer patients treated with anthracyclines and/or trastuzumab compared to 27.0% of untreated controls, suggesting no association.
Why the study?
Data regarding late gadolinium enhancement prevalence and patterns in cancer patients with anthracycline- and/or trastuzumab-related cardiomyopathy were confusing and ill-defined.
Is treatment with anthracyclines and/or trastuzumab associated with late gadolinium enhancement on cardiovascular magnetic resonance imaging in cancer patients?
Observational (n=398)
Is treatment with anthracyclines and/or trastuzumab associated with late gadolinium enhancement on cardiovascular magnetic resonance imaging in cancer patients?
Treatment with anthracyclines and/or trastuzumab is unlikely to be associated with late gadolinium enhancement, and its absence may help distinguish this specific cardiomyopathy from unrelated cardiomyopathies.
Answers are grounded in this paper and cite their sources.
Anthracycline/trastuzumab exposure was not linked to higher LGE; leaves open whether LGE absence distinguishes treatment-related cardiomyopathy.
AIMS: In cancer patients with cardiomyopathy related to anthracyclines and/or trastuzumab, data regarding late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging are confusing. The prevalence ranges from 0% to 30% and the patterns are ill-defined. Whether treatment with anthracyclines and/or trastuzumab is associated with LGE is unclear. We aimed to investigate these topics in a large cohort of consecutive cancer patients with suspected cardiotoxicity from anthracyclines and/or trastuzumab. METHODS AND RESULTS: We studied 298 patients, analysed the prevalence, patterns, and correlates of LGE, and determined their causes. We compared the findings with those from 100 age-matched cancer patients who received neither anthracyclines nor trastuzumab. Amongst those who received anthracyclines and/or trastuzumab, 31 (10.4%) had LGE. It had a wide range of extent (3.9-34.7%) and locations. An ischaemic pattern was present in 20/31 (64.5%) patients. There was an alternative explanation for the non-ischaemic LGE in 7/11 (63.6%) patients. In the age-matched patients who received neither anthracyclines nor trastuzumab, the prevalence of LGE was higher at 27.0%, while the extent of LGE and the proportion with ischaemic pattern were not different. CONCLUSION: LGE was present in only a minority. Its patterns and locations did not fit into a single unique profile. It had alternative explanations in virtually all cases. Finally, LGE was also present in cancer patients who received neither anthracyclines nor trastuzumab. Therefore, treatment with anthracyclines and/or trastuzumab is unlikely to be associated with LGE. The absence of LGE can help distinguish anthracycline- and/or trastuzumab-related cardiomyopathy from unrelated cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Modi et al. (2020) conducted an observational in Cancer patients with suspected cardiotoxicity (n=398). Anthracyclines and/or trastuzumab vs. Age-matched cancer patients who received neither anthracyclines nor trastuzumab was evaluated on Prevalence of late gadolinium enhancement (LGE). Late gadolinium enhancement was present in 10.4% of cancer patients treated with anthracyclines and/or trastuzumab compared to 27.0% of untreated controls, suggesting no association.
Synapse has enriched 10 related papers. Consider them for comparative context: